AtheroNova Inc., through its wholly-owned subsidiary, AtheroNova Operations, Inc., is a biotechnology company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans. In addition to its lead compound AHRO-001, AtheroNova plans to develop multiple applications for its patents-pending therapies in market sectors that include: cardiovascular disease, stroke, peripheral artery disease, dementia and Alzheimer's and erectile dysfunction, all of which have been linked to atherosclerosis. Additional areas of interest are obesity, lipomas and other lipid accumulations. Atherosclerosis and its related pharmaceutical expenses for these indications cost consumers more than $41 billion annually in the United States alone.
There are no upcoming events scheduled at this time. Sign up here to receive notices about upcoming events and press releases.
